Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum
Use
This test is useful for the diagnosis of inflammatory demyelinating diseases (IDD) that share a phenotype with neuromyelitis optica (NMO) spectrum disorder, including optic neuritis and transverse myelitis. It aids in diagnosing autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy, distinguishing NMOSD, acute disseminated encephalomyelitis, optic neuritis, and transverse myelitis from multiple sclerosis, and predicting a relapsing disease course. Correct diagnosis is vital as MOG-IgG related IDD could worsen with MS therapies, requiring distinct treatment approaches.
Special Instructions
Not provided.
Limitations
The MOG-IgG1 may drop below detectable levels when therapies for acute attack, such as IV methylprednisolone or plasmapheresis, are administered, or when immunosuppressants are used for attack prevention. This could lead to diagnostic challenges if not properly considered.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Myelin Oligodendrocyte Glycoprotein (MOG)-IgG1
Protein
LOINC Codes
- 90248-6 - MOG IgG1 SerPl Ql FC
- 90248-6 - MOG IgG1 SerPl Ql FC
Result Turnaround Time
5-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Patient Preparation
For optimal antibody detection, specimen collection should occur prior to initiation of immunosuppressant medication.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |